Cost Effectiveness of Prophylactic Intravenous Immune Globulin in Chronic Lymphocytic Leukemia
- 11 July 1991
- journal article
- research article
- Published by Massachusetts Medical Society in The New England Journal of Medicine
- Vol. 325 (2), 81-86
- https://doi.org/10.1056/nejm199107113250202
Abstract
A recent randomized controlled trial of intravenous immune globulin in patients with chronic lymphocytic leukemia and hypogammaglobulinemia demonstrated a statistically significant reduction in the rate of bacterial infections among patients who received intravenous immune globulin. We used decision-analysis techniques to determine whether prophylactic intravenous immune globulin is likely to result in an overall clinical benefit to patients who receive this treatment and to examine its cost effectiveness.Keywords
This publication has 13 references indexed in Scilit:
- NIH consensus conference. Intravenous immunoglobulin. Prevention and treatment of diseaseJAMA, 1990
- Clinical Uses of Intravenous ImmunoglobulinsAnnals of Internal Medicine, 1990
- Whose Utilities for Decision Analysis?Medical Decision Making, 1990
- Methodology for measuring health-state preferences—III: Population and context effectsJournal of Clinical Epidemiology, 1989
- Intravenous Immunoglobulin for the Prevention of Infection in Chronic Lymphocytic LeukemiaThe New England Journal of Medicine, 1988
- Rapid transient reversal of anemia and long-term effects of maintenance intravenous immunoglobulin for autoimmune hemolytic anemia in patients with lymphoproliferative disordersAmerican Journal Of Medicine, 1988
- ErratumClinical Infectious Diseases, 1987
- Cost-Effectiveness of Interventions to Prevent or Treat Coronary Heart DiseaseAnnual Review of Public Health, 1985
- Use of intravenous immunoglobulin in chronic lymphocytic leukemiaAmerican Journal Of Medicine, 1984
- PREVALENCE, INCIDENCE AND DURATIONAmerican Journal of Epidemiology, 1980